By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617


SEARCH JOBS
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit www.biogenidec.com


Key Statistics


Email:
Ownership: Public

Web Site: Biogen
Employees: 1700
Symbol: BIIB
 



Industry
Biotechnology


Collaborations

NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan  (crohn's & MS)

Dyax  Antibody phage display

Dow AgroSciences LLC 

Shire 

Sigma-Aldrich 

Sangamo 





Company News
Enigma Biomedical Group Signs Research Agreement With Biogen (BIIB) And Merck & Co. (MRK) For Novel Tau Imaging Agent 7/26/2016 10:32:21 AM
Speculation Heats Up on Biogen (BIIB) as an Acquisition Target or Starting a Buying Spree 7/25/2016 6:10:16 AM
Medidata Solutions, Inc. Cloud Technology Selected To Support Biogen (BIIB) Clinical Trials 7/22/2016 8:15:53 AM
As Biogen (BIIB) Boss Moves to the Bay Area, California Biotechs Pay Attention 7/22/2016 6:24:10 AM
Biogen (BIIB) Reports Second Quarter 2016 Revenues Of $2.9 Billion 7/21/2016 12:16:21 PM
Biogen (BIIB) CEO Steps Down Amid Stellar Q2 Financials, Hunt for New Leader Begins 7/21/2016 5:46:53 AM
Biogen (BIIB) And Sobi To Showcase Long-Term Efficacy And Safety Data From Extended Half-Life Hemophilia Therapies At World Federation Of Hemophilia 2016 World Congress 7/18/2016 9:58:01 AM
Biogen (BIIB) Hunts for New CIO 7/18/2016 6:40:18 AM
Evaluation: 7 Biopharma Companies’ Market Value Based on Pipelines 7/14/2016 6:31:45 AM
With Little Fanfare, Biogen (BIIB) Sneaks Lupus Drug Into a Phase I Trial 7/14/2016 6:19:07 AM
12345678910...
//-->